Search results
Local Leukemia & Lymphoma Society holds annual fundraiser for blood cancer research
Local 12 Cincinnati· 22 hours agoThe local chapter of the Leukemia and Lymphoma Society held its annual fundraiser to raise money for...
Patients Over 80 Still Benefit From Treatment for AML Blood Cancer
Alaska Superstation· 3 days agoSeniors over 80 with acute myeloid leukemia can safely and effectively take the standard targeted...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 4 days agoAML is a cancer of the blood and bone marrow and is the most common type of acute leukemia in adults. SENTI-202, a potential first-in-class Logic Gated ...
Earnings call: Aptose Biosciences targets AML treatment with tuspetinib By Investing.com
Investing.com· 2 days agoAptose Biosciences (NASDAQ:APTO) has focused its efforts on developing tuspetinib as part of a novel...
Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update
WJTV Jackson· 2 days agoAs of May 9, 2024, Ryvu's cash position was $59.0M, inclusive of the first tranche of €8M in venture debt from the EIB, obtained in March. This cash position, and other secured funding sources ...
Sutro Biopharma shares hold on luvelta prospects By Investing.com
Investing.com· 3 days agoLuvelta has the potential to serve a larger population than AbbVie (NYSE...Biopharma plans to...
Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and...
WJTV Jackson· 4 days agoIomab-B and Actimab-A are the only targeted radiotherapies in development for patients with relapsed/refractory acute myeloid leukemia
Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the 2024 European Hematology...
FOX 23 News Albany· 3 days agoUpdated data from the Phase I trial of RVU120 in patients with relapsed/refractory acute myeloid ...
Bio-Path Holdings Inc (BPTH) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...
GuruFocus.com via Yahoo Finance· 1 day agoQ & A Highlights Q: Can you provide an update on the progress of your lead product candidate, prexigebersen, for the treatment of acute myeloid ...
StockNews.com Upgrades Syros Pharmaceuticals (NASDAQ:SYRS) to Hold
ETF DAILY NEWS· 12 hours agoSyros Pharmaceuticals (NASDAQ:SYRS – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Wednesday. Several other equities ...